<?xml version="1.0" encoding="UTF-8"?><!--Transformation version 1.3--><legislativeDoc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://www.lexisnexis.com/xmlschemas/content/public/legislativedoc/1/" schemaVersion="1.0"><legislativeDocHead><citations><citeForThisResource citeDefinition="#7159#349#000032#     1#       331.15#">Va. Code Ann. § 32.1-331.15</citeForThisResource></citations><legislativeBodyInfo><jurisdiction><jurisSystem normalizedLongName="Virginia" normalizedShortName="VA"/></jurisdiction></legislativeBodyInfo></legislativeDocHead><legislativeDocBody><statute><level levelType="section"><anchor id="_32.1-331.15"/><heading><desig>§ 32.1-331.15.</desig><title>Prior authorization of prescription drug products; coverage under state plan</title></heading><level levelType="paragraph"><anchor id="_a"/><heading><desig>A.</desig></heading><bodyText><p> The Committee shall review prescription drug products to recommend prior authorization under the state plan in accordance with this article and regulations promulgated by the Board. Such review may be initiated by the Director, the Committee itself, or by written request of the Board. The Committee shall complete its recommendations to the Board within no more than six months from receipt of any such request.</p></bodyText></level><level levelType="paragraph"><anchor id="_b"/><heading><desig>B.</desig></heading><bodyText><p> Coverage under the state plan for any drug requiring prior authorization shall not be approved unless the prescriber obtains prior approval of such use in accordance with regulations promulgated by the Board and procedures established by the Department.</p><p>In formulating its recommendations to the Board, the Committee shall consider the potential impact on patient care and the potential fiscal impact of prior authorization on pharmacy, prescriber, hospitalization and outpatient costs. Any proposed regulation making a drug or category of drugs subject to prior authorization shall be accompanied by a statement of the estimated impact of such action on pharmacy, prescriber, hospitalization and outpatient costs.</p></bodyText></level><level levelType="paragraph"><anchor id="_c"/><heading><desig>C.</desig></heading><bodyText><p> The Committee shall not review any drug for which it has recommended or the Board has required prior authorization within the previous 12 months, unless new or previously unavailable relevant and objective information is presented.</p></bodyText></level><level levelType="paragraph"><anchor id="_d"/><heading><desig>D.</desig></heading><bodyText><p> Confidential proprietary information identified as such by a manufacturer or supplier in writing in advance and furnished to the Committee or the Board pursuant to this article shall not be subject to the disclosure requirements of the Virginia Freedom of Information Act (<citation type="statute" normalizedCite="VACODE 2.2-3700"><content><span normalizedCite="Va. Code Ann. § 2.2-3700">§ 2.2-3700<locator><locatorKey><keyName name="citeReference"/><keyValue value="#7159#349#000002#     2#         3700#"/></locatorKey></locator></span></content></citation> et seq.). The Board shall establish by regulation the means by which such confidential proprietary information shall be protected.</p></bodyText></level><history><historyGroup groupType="history-citation"><historyItem><bodyText><p><citation normalizedCite="1993 VA CH 537"><content><span normalizedCite="1993 Va. Ch. 537">1993, c. 537<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#1993#000537#"/></locatorKey></locator></span></content></citation>; <citation normalizedCite="2004 VA CH 855"><content><span normalizedCite="2004 Va. Ch. 855">2004, c. 855<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2004#000855#"/></locatorKey></locator></span></content></citation>.</p></bodyText></historyItem></historyGroup></history></level></statute></legislativeDocBody><metadata><dc:metadata xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:identifier identifierScheme="PGUID">urn:contentItem:5K0Y-PVD0-004G-K40P-00000-00</dc:identifier><dc:source sourceScheme="productContentSetIdentifier">10816</dc:source><dc:date dateType="last-updated">2016-06-15</dc:date></dc:metadata><publicationInfo><publicationName>CODE OF VIRGINIA </publicationName><copyright>Copyright © 2016  by Matthew Bender &amp; Company, Inc. a member of the LexisNexis Group. All rights reserved</copyright></publicationInfo><hierarchy><hierarchyLevel levelType="title"><heading><desig>TITLE 32.1.</desig><title>HEALTH</title></heading><hierarchyLevel levelType="chapter"><heading><desig>CHAPTER 10.</desig><title>DEPARTMENT OF MEDICAL ASSISTANCE SERVICES</title></heading><hierarchyLevel levelType="article"><heading><desig>ARTICLE 4.</desig><title>MEDICAID PRIOR AUTHORIZATION ADVISORY COMMITTEE</title></heading></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchy><classification classificationScheme="legal"><classificationItem><className>Administrative Law</className><classCode>Z3VpZD11cm46dG9waWM6NjMxMjc0MUIzQjkzNEM4MEI4NkZGQjVCREJCRDk4OUM7cGFyZW50Z3VpZD0</classCode><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6NzUxQjA0QThFQUYwNDQ3OUJGNkQ1MzBEQUNEMzQ2MTY7cGFyZW50Z3VpZD11cm46dG9waWM6RjgzODczMjc1N0UxNDFDNUJDNDc0Qzc1NzhCQkJCMzM</classCode></classificationItem><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6M0I4QTIzQjQ4MDcxNDczMThDMEUwOEQ0MkYzNEJFRkI7cGFyZW50Z3VpZD11cm46dG9waWM6QTkxRkE0MTcyQTY5NEY0Q0FBRDYzRDFCRDcyNzhERjc</classCode></classificationItem></classificationItem><classificationItem><className>Public Health &amp; Welfare Law</className><classCode>Z3VpZD11cm46dG9waWM6NDYwRTY1MDg3MTk5NDUyNkFFRDI1RjJBRERGQ0UxNzI7cGFyZW50Z3VpZD0</classCode><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6NjNEMkM3MDg5QzI2NDMwNDhGQkIxMUE5ODdERTNFQzE7cGFyZW50Z3VpZD11cm46dG9waWM6NjQ0NkMzMERDQTk0NEJDRjkzN0ZGMDA0RDQ1RTc5NDU</classCode></classificationItem><classificationItem><className>Pharmaceutical Services</className><classCode>Z3VpZD11cm46dG9waWM6NkVENDIzQUMyMTE1NDFCM0IxRjg5RDZDNjc1RDQ0QUE7cGFyZW50Z3VpZD11cm46dG9waWM6REY3QUUxQ0YxMDFENEE3MTg3QTU4QTdBNkRGMEVCMDc</classCode></classificationItem></classificationItem></classification><classificationGroup classificationScheme="indexing-terms"><classification classificationScheme="legal"><classificationItem><className>Business &amp; Corporate Compliance</className><classCode>Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI7cGFyZW50Z3VpZD0</classCode><classificationItem score="90"><className>Healthcare</className><classCode>Z3VpZD11cm46dG9waWM6NkUxMkVDQjJDOEY5NDVDQ0E5NTFEMTlDMjIwNzVERjc7cGFyZW50Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI</classCode></classificationItem></classificationItem></classification></classificationGroup></metadata></legislativeDoc>